secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001641172-25-006649
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics approves 1-for-14 reverse stock split effective May 5, 2025
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-14 ratio, effective 12:01 a.m. ET on May 5, 2025.
- Intended to bring PTIX into compliance with Nasdaq minimum bid price rule 5550(a)(2).
- Share count to drop from ~8.24M to ~588,750; fractional shares rounded up.
- Stockholders approved split on April 18, 2025 with ratio range 1:10 to 1:20; board set at 1:14.
- Symbol PTIX unchanged; new CUSIP 74365N301; no change in authorized shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000164117225006649/0001641172-25-006649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000164117225006649/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-006649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer